Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
2.
Pediatr Blood Cancer ; 65(3)2018 03.
Article in English | MEDLINE | ID: mdl-29171168

ABSTRACT

Incontinentia pigmenti (IP) is a genetic disorder caused by mutations in IKBKG, leading to functional loss of nuclear factor kappa B (NF-ĸB). We report the case of a 6-month-old female child with IP who presented with unilateral nystagmus and was found to have a pilocytic astrocytoma with leptomeningeal spread. Enhanced understanding of the relationship between NF-ĸB, along with its upstream regulators, and tumorigenesis may shed light on whether a subset of patients with IP may be at increased risk for neoplasia.


Subject(s)
Astrocytoma/epidemiology , Incontinentia Pigmenti/epidemiology , Nystagmus, Pathologic/etiology , Astrocytoma/complications , Female , Humans , Incontinentia Pigmenti/complications , Infant , Meningeal Carcinomatosis/complications , Meningeal Carcinomatosis/epidemiology
4.
Pediatr Dermatol ; 34(4): 413-421, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28556385

ABSTRACT

BACKGROUND/OBJECTIVES: The nonselective beta-blocker propranolol is the current criterion standard for treatment of infantile hemangiomas (IHs) and the first therapy that the U.S. Food and Drug Administration has approved for the condition, but concern about adverse effects, such as bronchospasm, hypoglycemia, and sleep disturbances, has sparked interest in the use of alternative agents such as the selective ß1 antagonist atenolol. Our aim was to compare the efficacy and adverse effect profiles of atenolol with those of propranolol in the treatment of IHs in a retrospective noninferiority trial. METHODS: Twenty-seven children with IHs treated with atenolol according to the Cleveland Clinic foundation's standardized clinical assessment and management plan (SCAMP) met inclusion criteria and were compared with a matched group of 53 children with IHs treated with propranolol. Three reviewers assessed response to therapy using a modified version of the previously validated Hemangioma Activity Score (HAS). RESULTS: The mean change in HAS was -2.94 ± 1.20 for patients treated with atenolol and -2.96 ± 1.42 for those treated with propranolol. There was no statistically significant difference in pre- and posttreatment modified HAS scores between the two groups (p = 0.60). There was no significant difference in the overall rate of adverse effects (p = 0.10), although 11% of patients treated with propranolol experienced reactive airway symptoms, whereas this was not seen in any of the patients treated with atenolol. CONCLUSION: Our study supports previous findings that atenolol is at least as effective as propranolol for treatment of IHs and poses less risk of bronchospasm. Our SCAMP proposes guidelines for dosing and monitoring parameters.


Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Atenolol/therapeutic use , Hemangioma/drug therapy , Propranolol/therapeutic use , Adrenergic beta-Antagonists/adverse effects , Atenolol/adverse effects , Case-Control Studies , Female , Humans , Infant , Infant, Newborn , Male , Propranolol/adverse effects , Retrospective Studies , Treatment Outcome
6.
Curr Opin Pediatr ; 27(4): 454-9, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26087423

ABSTRACT

PURPOSE OF REVIEW: Since 2008, beta-blockers have become first-line treatment for infantile hemangiomas, the most common tumor of infancy. Their role is also being explored in the treatment of other childhood vascular tumors. RECENT FINDINGS: Recent research has demonstrated that propranolol is a more effective and safer treatment for infantile hemangiomas than previous therapeutic options. It is most effective when initiated during the tumor's proliferative phase. Other oral beta-blockers such as atenolol and nadolol are less studied, but may offer similar efficacy. Topical beta-blockers such as timolol appear to be effective in treating small, superficial infantile hemangiomas. Beta-blockers have shown variable results for the treatment of other vascular tumors of childhood, such as pyogenic granulomas, kaposiform hemangioendotheliomas, and tufted angiomas. SUMMARY: Propranolol has revolutionized the treatment of infantile hemangiomas, and other beta-blockers provide promising alternatives. Unanswered questions remain about the optimal choice of agent, delivery mechanism, dosage, need for pretreatment evaluation or ongoing monitoring, and duration of therapy. The role of beta-blockers in treating other types of vascular tumors requires further study.


Subject(s)
Adrenergic beta-Antagonists/administration & dosage , Facial Neoplasms/drug therapy , Neurocutaneous Syndromes/drug therapy , Propranolol/administration & dosage , Skin Neoplasms/drug therapy , Vascular Neoplasms/drug therapy , Administration, Oral , Administration, Topical , Atenolol/administration & dosage , Child, Preschool , Facial Neoplasms/pathology , Humans , Infant , Neoplastic Syndromes, Hereditary , Neurocutaneous Syndromes/pathology , Skin Neoplasms/pathology , Timolol/administration & dosage , Treatment Outcome , Vascular Neoplasms/pathology
7.
Int J Womens Dermatol ; 1(1): 31-36, 2015 Feb.
Article in English | MEDLINE | ID: mdl-28491952

ABSTRACT

Over 200,000 children have been adopted into United States (US) families from abroad since the year 2000. Health care providers who care for children adopted internationally should be aware of the spectrum of illnesses seen in this population, and should be prepared to encounter potentially unusual situations. An appreciation for the unique pre-adoption exposures and vulnerabilities inherent in international adoption is critical for proper diagnosis and treatment of this heterogeneous group of children. It is important to consider the impact of potential early childhood stressors such as nutritional, sensory, and emotional deprivation, trauma and abuse, as well as prenatal exposures to drugs, alcohol, and infectious diseases. Providers must also take into account international variation in health care practices, including immunization, treatment, surgical, and hygiene standards. The differential diagnosis for cutaneous eruptions in children adopted internationally is broad and must encompass endemic systemic illnesses with skin manifestations, such as measles, tuberculosis, leprosy, and congenital syphilis, and primary dermatologic diseases such as scabies and bacterial and fungal infections. The importance of maintaining a broad differential and open mind when addressing the dermatologic needs of these children cannot be overemphasized.

SELECTION OF CITATIONS
SEARCH DETAIL
...